A Randomized Phase II Study of Pembrolizumab an anti-PD (programmed cell death)-1 Antibody in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
This study is being done to see what effects the combination of pembrolizumab and carboplatin have on breast cancer compared to carboplatin alone.
The primary objective is to determine the disease control rate (including CR, PR and stable disease as defined by RECIST 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin or carboplatin alone.
Participants will not be paid for their participation.
- IRB Number: 1802063021 (TBCRC044)
- Research Study Identifier: TX8819
- Principal Investigator: Kathy Miller, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required